Independent Study Demonstrates Effectiveness of Kiva®System for Patients With Osteolytic Vertebral Metastases
February 25, 2014The first head-to-head study found that Kiva System was as effective as balloon kyphoplasty in reducing pain associated with osteolytic vertebral body metastases and had no extravasation (cement leakage) while BKP showed a nearly 10 percent leakage rate.
More »
VentiRx Pharmaceuticals Presents Phase 1 Data on VTX-2337 at 2014 Multidisciplinary Head and Neck Cancer Symposia
February 20, 2014Encouraging signs of efficacy provided the rationale for the ongoing randomized placebo-controlled Phase 2 study of VTX-2337 in combination with cetuximab, platinum and 5-FU in patients with recurrent or metastatic SCCHN.
More »
Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director
February 13, 2014Dr. McGovern is a board-certified cardiologist with over 20 years of experience developing lipid-regulating therapies: pravastatin (Pravachol®), extended-release (ER) niacin (Niaspan®), ER niacin/lovastatin (Advicor®) and ER niacin /simvastatin (Simcor®).
More »